What's New

Advancing Hope: AFTD Staff Attend NORD Breakthrough Summit in Washington, DC

Shana Dodge, PhD, AFTD’s Director of Research Engagement and Meghan Buzby, MBA, AFTD’s Director of Advocacy and Volunteer Engagement attended the National Organization for Rare Disorders (NORD) Breakthrough Summit, held…

Read More about Advancing Hope: AFTD Staff Attend NORD Breakthrough Summit in Washington, DC

GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP

South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a clinical trial evaluating a drug for PSP. While the drug failed to show…

Read More about GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP

Dear HelpLine: Navigating Travel During the Holidays

Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with…

Read More about Dear HelpLine: Navigating Travel During the Holidays

A Conversation with Alector’s Vice President of Clinical Development

Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to…

Read More about A Conversation with Alector’s Vice President of Clinical Development

Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN

Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the…

Read More about Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN

November 24, 2024: In-Person Meet & Greet in Manchester, NH

Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the…

Read More about November 24, 2024: In-Person Meet & Greet in Manchester, NH

AFTD Webinar: Diagnosing Primary Progressive Aphasia

With primary progressive aphasia (PPA), problems with language and communication typically deteriorate gradually over time. Initial symptoms are sometimes attributed to anxiety or stress until the ongoing symptoms become disruptive…

Read More about AFTD Webinar: Diagnosing Primary Progressive Aphasia

Tell Your Legislators: Reauthorize Funding for the Older Americans Act

You may think that because frontotemporal degeneration strikes many people in the middle of their life, that the Older Americans Act may not apply to you. But the OAA provides…

Read More about Tell Your Legislators: Reauthorize Funding for the Older Americans Act

Advancing Hope: AFTD hosts 2024 FTD Research Roundtable Meeting

The FTD Research Roundtable is an annual program designed to accelerate FTD drug development by convening various scientific stakeholders to identify common challenges and advance solutions for FTD clinical trials.…

Read More about Advancing Hope: AFTD hosts 2024 FTD Research Roundtable Meeting

AC Immune and Life Molecular Imaging Announce FDA Fast Track Designation for Tau PET Tracer

Swiss biopharmaceutical company AC Immune announced in late August that its partner, German biopharmaceutical company Life Molecular Imaging (LMI), received a Fast Track Designation from the US Food and Drug…

Read More about AC Immune and Life Molecular Imaging Announce FDA Fast Track Designation for Tau PET Tracer